This is a working overview of WADA prohibited list, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-03 and is reviewed periodically as new material appears.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
== Controversies == SEL1L gene (sel-1 suppressor of Lin-12-like Caenorhabdits elegans) is a negative regulator of the Notch signaling pathway that is responsible for pancreatic endocrine cell development. SEL1L gene is located on chromosome 14q24.3-31. The locus of SEL1L is near to D14S67 marker used for identification of IDDM 11 so that SEL1L gene can serve as a candidate gene for IDDM11. However, the present researchers are object to this thesis. The present researchers use LD (Linkage disequilibrium) analyses and TDT (transmission disequilibrium test) to analyze the SEL1L gene among Danish and Sardinian families. The research result indicates that the SEL1L gene is not supposed to a candidate gene for IDDM11. In addition, other candidate genes for IDDM11 could be tested and identified by using single nucleotide polymorphism (SNP) technology. The following table shows some candidate genes for IDDM11.
APCs naturally have a role in fighting tumors, via stimulation of B and cytotoxic T cells to respectively produce antibodies against tumor-related antigen and kill malignant cells. Dendritic cells, presenting tumor-specific antigen to T cells, are key to this process. Cancer therapies have included treating the patient with increased numbers of dendritic cells or cancer-specific T cells. However, newer therapies have turned to genetically engineered artificial antigen-presenting cells designed to prime the immune system to attack malignant cells. Some artificial APCs are derived from human cells; others are acellular, containing MHC proteins, co-stimulatory molecules and the necessary peptides. The APC activator IMP321 is being tested in clinical trials to accelerate the immune reaction to eliminate metastatic breast cancer or melanoma. Antigen: protease degradation on YouTube – PMAP animation Antigen-Presenting+Cells at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Aquarium granuloma (fish-tank granuloma, swimming-pool granuloma) Borderline lepromatous leprosy Borderline leprosy Borderline tuberculoid leprosy Buruli ulcer (Bairnsdale ulcer, Searl ulcer, Searle's ulcer) Erythema induratum (Bazin disease) Histoid leprosy Lepromatous leprosy Leprosy (Hansen's disease) Lichen scrofulosorum (tuberculosis cutis lichenoides) Lupus vulgaris (tuberculosis luposa) Miliary tuberculosis (disseminated tuberculosis, tuberculosis cutis acuta generalisata, tuberculosis cutis disseminata) Mycobacterium avium-intracellulare complex infection Mycobacterium haemophilum infection Mycobacterium kansasii infection Papulonecrotic tuberculid Primary inoculation tuberculosis (cutaneous primary complex, primary tuberculous complex, tuberculous chancre) Rapid-growing Mycobacterium infection Scrofuloderma (tuberculosis cutis colliquativa) Tuberculosis cutis orificialis (acute tuberculous ulcer, orificial tuberculosis) Tuberculosis verrucosa cutis (lupus verrucosus, prosector's wart, warty tuberculosis) Tuberculous cellulitis Tuberculous gumma (metastatic tuberculous abscess, metastatic tuberculous ulcer) Tuberculoid leprosy
=== Sweden === The Swedish Armed Forces use ration packs from the Swedish-developed 24 hour meals. 24 hour meals have a long range of menus (approx. 200) and can deliver both freezedried and wet meals. The Swedish concept (combat edition) consists of several versions for different use, in all climate zones, and various types of missions. Examples of different types of rations: 1-course (patrolration), 2-course, 3-course and 4-course versions with a variation of 40 different meals, both wet and dry. The rations varies from 1300 kcal to 5000 kcal. The ration is packed in a transparent durable plastic bag that is resealable with a ziplock. The contents are 1–4 main meals with energy bars, protein bars, nuts, energy drinks, whole wheat bread, peanut butter, desserts and spices for example. The durable bag change size depending on the version for optimal space usage in cartons and soldiers' backpacks. 24 hour meals have been developed at a rapid pace and are currently producing their 5th generation (first in 2008). R&D are working close with soldiers in Scandinavia and various missions around the world.
Sources: en.wikipedia.org
==== Incremental ==== An incremental backup stores data changed since a reference point in time. Duplicate copies of unchanged data are not copied. Typically a full backup of all files is made once or at infrequent intervals, serving as the reference point for an incremental repository. Subsequently, a number of incremental backups are made after successive time periods. Restores begin with the last full backup and then apply the incrementals. Some backup systems can create a synthetic full backup from a series of incrementals, thus providing the equivalent of frequently doing a full backup. When done to modify a single archive file, this speeds restores of recent versions of files.
However, later on, within a more complex cellular environment, these highly hydrophobic LCRs became inappropriate or even toxic from a protein interaction perspective and have been selected against ever since. In addition, they further hypothesize that the very early protopeptides did not have a nucleic acid binding role, because DNA and RNA-binding LCRs are highly enriched in glycine, arginine and lysine, however, arginine and lysine are not among the amino acids of the proposed early genetic code.
== Awards and recognition == Fellow, American Association for the Advancement of Science (1995) Fellow, Academy of Toxicological Sciences (2000) Public Communications Award, Society of Toxicology (2014) Excellence in Pharmacology/Toxicology Lifetime Award, PhRMA Foundation (2015) David Rall Medal, National Academy of Medicine (2020) Merit Award, Society of Toxicology (2024)
After Trump's victory in the 2016 elections, Sanders suggested the Democratic Party undergo a series of reforms and that it "break loose from its corporate establishment ties and, once again, become a grass-roots party of working people, the elderly and the poor." He drew parallels between his campaign and that of the Labour Party in the 2017 UK general election. He wrote in The New York Times that "the British elections should be a lesson for the Democratic Party" and urged the Democrats to stop holding on to an "overly cautious, centrist ideology", arguing that "momentum shifted to Labour after it released a very progressive manifesto that generated much enthusiasm among young people and workers." He had earlier praised Jeremy Corbyn's stance on class issues. Sanders is one of two independents in the Senate, along with Angus King, both of whom caucus with the Democrats.
== Biological role == It was not recognized until the 1970s, but nickel is known to play an important role in the biology of some plants, bacteria, archaea, and fungi. Nickel enzymes such as urease are considered virulence factors in some organisms. Urease catalyzes hydrolysis of urea to form ammonia and carbamate. NiFe hydrogenases can catalyze oxidation of H2 to form protons and electrons; and also the reverse reaction, the reduction of protons to form hydrogen gas. A nickel-tetrapyrrole coenzyme, cofactor F430, is present in methyl coenzyme M reductase, which can catalyze the formation of methane, or the reverse reaction, in methanogenic archaea (in +1 oxidation state). One of the carbon monoxide dehydrogenase enzymes consists of an Fe-Ni-S cluster. Other nickel-bearing enzymes include a rare bacterial class of superoxide dismutase and glyoxalase I enzymes in bacteria and several eukaryotic trypanosomal parasites (in other organisms, including yeast and mammals, this enzyme contains divalent Zn2+). Dietary nickel may affect human health through infections by nickel-dependent bacteria, but nickel may also be an essential nutrient for bacteria living in the large intestine, in effect functioning as a prebiotic. The US Institute of Medicine has not confirmed that nickel is an essential nutrient for humans, so neither a Recommended Dietary Allowance (RDA) nor an Adequate Intake have been established. The tolerable upper intake level of dietary nickel is 1 mg/day as soluble nickel salts. Estimated dietary intake is 70 to 100 μg/day; less than 10% is absorbed.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.